• MHY1485: A Practical mTOR Activator Workflow

  2026-08-19

  MHY1485 provides a pharmacological way to activate mTOR while examining autophagy suppression, pathway-dependent proliferation, and tissue growth. This guide translates mTORC1 findings from nasopharyngeal carcinoma research into controlled signaling, autophagy, and ovarian follicle assay workflows, with practical troubleshooting for solubility and readout interpretation.

• MG-262 and Muscle Aging: A Proteostasis Strategy

  2026-08-19

  Muscle aging research is moving beyond single-pathway models of protein quality control. This thought-leadership article positions MG-262 (Z-Leu-Leu-Leu-B(OH)2) as a reversible pharmacological probe for separating proteasome function from chaperone-mediated autophagy, while providing a translational framework for proteasome inhibition assays, apoptosis research, and disease-relevant muscle models.

• HyperScribe Co-transcription mRNA Synthesis Kit Plus

  2026-08-18

  Build translation-ready, ARCA-capped and polyadenylated mRNA for vaccine research, reporter assays, RNAi, and mechanistic studies. This practical guide connects the HyperScribe workflow with an HCC nanovaccine study while separating validated product specifications from assay-specific optimization choices.

• ATRX Loss Sensitizes Glioma to RTK Inhibitors

  2026-08-18

  The reference study identifies ATRX deficiency as a potential genetic marker of increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data with temozolomide support incorporating ATRX status into experimental design and the interpretation of RTK inhibitor trials, while remaining hypothesis-generating rather than clinically conclusive.

• Gastrodin, AT1 Signaling, and Reactive Astrocytes

  2026-08-17

  The 2024 study by Zuo and colleagues identifies a microglia-to-astrocyte signaling pathway in which inflammatory conditioned medium alters renin–angiotensin system components, SIRT3, and astrocyte phenotype markers. Its use of azilsartan to perturb AT1 signaling strengthens the case that AT1 participates in gastrodin-mediated regulation of reactive astrocytes, while also highlighting the complexity of interpreting A1/A2 marker changes.

• DiscoveryProbe FDA-approved Drug Library: Assay Guide

  2026-08-17

  Learn how DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) can support reproducible cell viability, proliferation, and cytotoxicity workflows through defined compound formatting, broad pharmacology, and practical screening design. The article connects assay optimization with drug repositioning screening and evidence-aware data interpretation.

• TAK-242: TLR4 Inhibition Workflow Guide

  2026-08-16

  TAK-242 (Resatorvid) provides a focused way to dissect LPS-triggered inflammation, macrophage phagocytosis, and host–pathogen signaling. This guide connects dose planning and assay controls with the recent Salmonella haem study, while separating validated evidence from practical workflow recommendations.

• Gramine: Reliable Ferroptosis Assay Workflows

  2026-08-15

  This scenario-based guide explains how Gramine (SKU N2337) can support reproducible viability, proliferation, and ferroptosis experiments in triple-negative breast cancer models. It connects published CUL3–MTDH findings with practical choices for stock preparation, controls, data interpretation, and product selection.

• Visceral ATM-Targeted TACE Silencing in Obesity

  2026-08-14

  Yong, Song, and Kim developed an ATS-9R-based nonviral delivery strategy to silence TACE selectively in visceral adipose tissue macrophages. Their findings connect tissue-selective gene delivery with reduced adipose inflammation and improved obesity-induced type 2 diabetes, providing a useful framework for targeted metabolic disease research.

• JC-1 Mitochondrial Membrane Potential Assay Workflow

  2026-08-14

  Build a ratiometric mitochondrial membrane potential assay around JC-1 to distinguish depolarization from simple changes in cell number or fluorescence intensity. This workflow combines CCCP controls, reproducible imaging or plate-reader acquisition, and troubleshooting guidance for apoptosis assay, cytotoxicity, and mitochondrial function analysis.

• Spatially Patterned Kidney Assembloids for Disease Modeling

  2026-08-13

  Huang and colleagues developed mouse and human kidney progenitor assembloids that reproduce spatial relationships between nephron and collecting-system progenitors, improving tissue organization, maturation, and functional capacity. Their genome-edited PKD2-deficient assembloids also provide a higher-fidelity platform for studying polycystic kidney disease and interactions among cystic epithelium, stroma, and macrophages.

• Single-Cell Basis of Ciprofloxacin–Tetracycline Antagonism

  2026-08-13

  The reference study shows that ciprofloxacin–tetracycline antagonism is driven primarily by improved survival under combination treatment rather than by a simple reduction in growth inhibition. Its microfluidic single-cell approach links nutrient-dependent initial growth, SOS-response heterogeneity, and bacterial cell death, providing a more resolved framework for interpreting antibiotic combinations.

• MRE11 Lactylation and TNBC Radioresistance

  2026-08-12

  The reference study identifies lactate-dependent MRE11 Lys673 lactylation as a DNA-repair mechanism that supports radiotherapy resistance in triple-negative breast cancer. It further shows that Saikosaponin D activates an HIF1α/HDAC5 pathway to remove this modification, establishing a mechanistic link between tumor metabolism, epigenetic regulation, and radiation response.

• Ciprofloxacin Hydrochloride at Single-Cell Scale

  2026-08-12

  Ciprofloxacin hydrochloride is a fluoroquinolone antibiotic whose effects depend on DNA damage, growth state, and cellular heterogeneity. This article translates single-cell evidence into practical assay design for antibiotic-interaction studies while distinguishing antibacterial, immunomodulatory, and translational claims.

• Imatinib Hydrochloride: Kinase Research Guide

  2026-08-11

  Imatinib hydrochloride, also called STI571 hydrochloride, is a multi-target tyrosine kinase inhibitor for cancer research involving v-Abl, c-Kit, and PDGFR signaling. Its reported biochemical and cellular benchmarks support chronic myelogenous leukemia research and gastrointestinal stromal tumor research, but assay conditions and salt-form differences must be controlled.

15125 records 1/1009 page Next 12345 下5页 Last page